Epirubicin induces apoptosis in osteoblasts through death-receptor and mitochondrial pathways
Tóm tắt
Epirubicin is an anthracycline and is widely used in tumor treatment, but has toxic and undesirable side effects on wide range of cells and hematopoietic stem cells (HSC). Osteoblasts play important roles in bone development and in supporting HSC differentiation and maturation. It remains unknown whether epirubicin-induced bone loss and hematological toxicity are associated with its effect on osteoblasts. In primary osteoblast cell cultures, epirubicin inhibited cell growth and decreased mineralization. Moreover, epirubicin arrested osteoblasts in the G2/M phase, and this arrest was followed by apoptosis in which both the extrinsic (death receptor-mediated) and intrinsic (mitochondrial-mediated) apoptotic pathways were evoked. The factors involved in the extrinsic apoptotic pathway were increased FasL and FADD as well as activated caspase-8. Those involved in the intrinsic apoptotic pathway were decreased Bcl-2; increased reactive oxygen species, Bax, cytochrome c; and activated caspase-9 and caspase-3. These results demonstrate that epirubicin induced osteoblast apoptosis through the extrinsic and intrinsic apoptotic pathways, leading to the destruction of osteoblasts and consequent lessening of their functions in maintaining bone density and supporting hematopoietic stem cell differentiation and maturation.
Tài liệu tham khảo
Khasraw M, Bell R, Dang C (2012) Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21(2):142–149. https://doi.org/10.1016/j.breast.2011.12.012
Azab SS, El-Demerdash E, Abdel-Naim AB et al (2005) Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines. Biochem Pharmacol 70(5):725–732. https://doi.org/10.1016/j.bcp.2005.03.036
Salvatorelli E, Guarnieri S, Menna P et al (2006) Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition. J Biol Chem 281(16):10990–11001. https://doi.org/10.1074/jbc.M508343200
Ozkan A, Fiskin K (2004) Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol 56(4):435–444
Chang WT, Hsieh BS, Cheng HL et al (2014) Progesterone augments epirubicin-induced apoptosis in HA22T/VGH cells by increasing oxidative stress and upregulating Fas/FasL. J Surg Res 188(2):432–441. https://doi.org/10.1016/j.jss.2014.01.063
Chang WT, Cheng HL, Hsieh BS et al (2014) Progesterone increases apoptosis and inversely decreases autophagy in human hepatoma HA22T/VGH cells treated with epirubicin. Sci. World J. https://doi.org/10.1155/2014/567148
Jonat W, Kaufmann M, Sauerbrei W et al (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20(24):4628–4635. https://doi.org/10.1200/JCO.2002.05.042
Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19(14):3306–3311. https://doi.org/10.1200/JCO.2001.19.14.3306
Nurgalieva Z, Liu CC, Du XL (2011) Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Med Oncol 28(3):716–725. https://doi.org/10.1007/s12032-010-9512-5
Georgiou KR, Hui SK, Xian CJ (2012) Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells 1(3):205–224
Garrett RW, Emerson SG (2009) Bone and blood vessels: the hard and the soft of hematopoietic stem cell niches. Cell Stem Cell 4(6):503–506. https://doi.org/10.1016/j.stem.2009.05.011
Bianco P (2011) Bone and the hematopoietic niche: a tale of two stem cells. Blood 117(20):5281–5288. https://doi.org/10.1182/blood-2011-01-315069
Hu YC, Cheng HL, Hsieh BS et al (2012) Arsenic trioxide affects bone remodeling by effects on osteoblast differentiation and function. Bone 50(6):1406–1415. https://doi.org/10.1016/j.bone.2012.03.012
Hung TC, Huang LW, Su SJ et al (2011) Hemeoxygenase-1 expression in response to arecoline-induced oxidative stress in human umbilical vein endothelial cells. Int J Cardiol 151(2):187–194. https://doi.org/10.1016/j.ijcard.2010.05.015
Hsieh BS, Huang LW, Su SJ et al (2011) Combined arginine and ascorbic acid treatment induces apoptosis in the hepatoma cell line HA22T/VGH and changes in redox status involving the pentose phosphate pathway and reactive oxygen and nitrogen species. J Nutr Biochem 22(3):234–241. https://doi.org/10.1016/j.jnutbio.2010.01.009
Dickinson BC, Chang CJ (2008) A targetable fluorescent probe for imaging hydrogen peroxide in the mitochondria of living cells. J Am Chem Soc 130(30):9638–9639. https://doi.org/10.1021/ja802355u
Olive PL, Banath JP (2006) The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1(1):23–29. https://doi.org/10.1038/nprot.2006.5
Cheng HL, Su SJ, Huang LW et al (2010) Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis: involvement of STAT3 and RhoA activation. Mol Cancer 9(126). https://doi.org/10.1186/1476-4598-9-126
Chang KL, Cheng HL, Huang LW et al (2009) Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. Cancer Lett 276(1):14–20. https://doi.org/10.1016/j.canlet.2008.10.033
Minotti G, Menna P, Salvatorelli E et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185–229. https://doi.org/10.1124/pr.56.2.6
Du P, Cao H, Wu HR et al (2013) Blocking Bcl-2 leads to autophagy activation and cell death of the HEPG2 liver cancer cell line. Asian Pac J Cancer Prev 14(10):5849–5854
Anderson HC, Sipe JB, Hessle L et al (2004) Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol 164(3):841–847
Orimo H (2010) The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch 77(1):4–12
Fan C, Georgiou KR, McKinnon RA et al (2016) Combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil causes trabecular bone loss, bone marrow cell depletion and marrow adiposity in female rats. J Bone Miner Metab 34(3):277–290. https://doi.org/10.1007/s00774-015-0679-x
Czabotar PE, Lessene G, Strasser A et al (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15(1):49–63. https://doi.org/10.1038/nrm3722
Caulfield AJ, Lathem WW (2014) Disruption of fas-fas ligand signaling, apoptosis, and innate immunity by bacterial pathogens. PLoS Pathog 10(8):e1004252. https://doi.org/10.1371/journal.ppat.1004252
Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25(34):4798–4811. https://doi.org/10.1038/sj.onc.1209608
Tait SW, Green DR (2010) Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11(9):621–632. https://doi.org/10.1038/nrm2952
Fogli S, Danesi R, Gennari A et al (2002) Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol 13(6):919–927
Taichman RS, Emerson SG (1994) Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. J Exp Med 179(5):1677–1682
Mirzaei HR, Sabet Rasekh P, Nasrollahi F et al (2013) Dose-dense epirubicin and cyclophosphamide followed by docetaxel as adjuvant chemotherapy in node-positive breast cancer. Int J Breast Cancer. https://doi.org/10.1155/2013/404396